Other clinical trials in phase 1/2a are underway to assess the safety and efficacy of a monoclonal antibody that inhibit CD73, MEDI9447, combined with chemotherapy and radiotherapy in patients with advanced solid tumors, including CRC [121]. The gene discussed is NT5E; the disease is colorectal carcinoma.